Available Technologies

Browse Penn-owned technologies available for licensing.

HOME SEARCH RSS FEED

Pharmaceutical therapeutic for the treatment of respiratory diseases

Description:

 

Brief Description:

 

Histone deacetylase (HDAC) inhibitors such as Trichostatin A to treat bronchoconstrictive diseases including asthma and chronic obstructive pulmonary disorder (COPD)

 

Technology:

 

Asthma and COPD are diseases of variable airflow obstruction affecting over 40 million Americans. Although some patients respond to conventional therapies, patients with severe disease disproportionately utilize healthcare resources. Therefore, new methods for treating asthma and COPD are needed.

 

Histone deacetylase (HDAC) inhibitors improve pulmonary function in animal models. The HDAC inhibitors, small molecules such as Trichostatin A, reverse the effects of drug-induced broncho-constriction by acting directly on pulmonary smooth muscle cells, a novel mechanism of action. The use of HDAC inhibitors alone, or in combination with known bronchodilators or corticosteroids, has therapeutic potential and offers increased therapeutic efficacy for the treatment of chronic obstructive pulmonary disorders.

 

 

Trichostatin A (TSA) che| HDAC Inhibitor

 

Applications:

 

•       Small molecule therapeutic that dilates bronchi to treat asthma and other lung diseases

 

Advantages:

 

•       Potential combination therapy

•       Use for HDAC inhibitors for the treatment of broncho-constrictive disorders

 

Stage of Development:

 

•       Proof of concept in vivo

 

Intellectual Property:

 

1.       US 9,827,212 B2

 

Reference Media

 

Banerjee, A. et al.; AmJ Respir Cell Mol Biol 2012 Feb; 46(2): 132.

 

Desired Partnerships:

 

1.       License

 

Docket #: V4967

Download pdf


Patent Information:
For Information, Contact:
Viviane Martin
Director, PSOM Licensing Group
University of Pennsylvania
215-746-4275
martinv@upenn.edu
Inventors:
Jonathan Epstein
Reynold Panettieri
Keywords: